Citigroup’s Ascendis Pharma A/S ASND Stock Holding History

Citigroup’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.74M	Buy	+16,400	New	+$4.15M	﹤0.01%	2335
2026 Q2	–	Sell	-12,000	Closed	-$2.74M	–	5721
2026 Q1	$2.74M	Sell	12,000 -63,900	-84%	-$14.3M	﹤0.01%	2449
2025 Q4	$16.2M	Buy	+75,900	New	+$15.7M	0.01%	1224
2024 Q3	–	Sell	-12,500	Closed	-$1.7M	–	5674
2024 Q2	$1.7M	Sell	12,500 -12,300	-50%	-$1.67M	﹤0.01%	2476
2024 Q1	$3.75M	Sell	24,800 -3,400	-12%	-$485K	﹤0.01%	1930
2023 Q4	$3.55M	Buy	28,200 +3,200	+13%	+$319K	﹤0.01%	1824
2023 Q3	$2.34M	Hold	25,000	–	–	﹤0.01%	1889
2023 Q2	$2.23M	Hold	25,000	–	–	﹤0.01%	2100
2023 Q1	$2.68M	Buy	25,000 +800	+3%	+$91.5K	﹤0.01%	1828
2022 Q4	$2.96M	Buy	+24,200	New	+$2.81M	﹤0.01%	1781

Other funds holding ASND

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

ARS Investment Partners New York $2.23B AUM 74.02% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Braun Stacey Associates New York $3.48B AUM 48.73% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Citigroup's ASND Position: Q3 2026 in Review

Citigroup increased its Ascendis Pharma A/S (ASND) stake by 167% in Q3 2026, buying an estimated $12.1M and bringing the position to 76,508 shares worth $17.4M. The position accounts for 0.01% of the portfolio, ranked #1272.

Citigroup first reported a position in ASND in Q1 2015 and has held it in 36 quarters since. 133 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

Citigroup held 76,508 shares of Ascendis Pharma A/S worth $17.4M as of Q3 2026.
Citigroup bought 47,815 Ascendis Pharma A/S shares in Q3 2026, an estimated $12.1M.
Ascendis Pharma A/S made up 0.01% of Citigroup's portfolio in Q3 2026, its #1272 holding.
Citigroup first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 36 quarters since.
133 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.